Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838712 | 0.83 | KDM4E (0.41) | KDM4EALDH1A1MAPTPKMHRH3 | |
| SCHEMBL188362 | 0.81 | ADRA2C (0.42) | KDM4EALDH1A1MAPTLMNAGAA | |
| SCHEMBL2033939 | 0.80 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTTSHRGAA | |
| SCHEMBL14940417 | 0.79 | ALDH1A3 (0.45) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL27865306 | 0.78 | NCF1 (0.38) | KDM4EALDH1A1MAPTPKMHRH3 | |
| SCHEMBL16462683 | 0.77 | GAA (0.53) | KDM4EALDH1A1MAPTHRH3CYP2D6 | |
| SCHEMBL1813837 | 0.76 | AKR1C3 (0.42) | KDM4EALDH1A1MAPTTSHRLMNA | |
| SCHEMBL1814799 | 0.76 | ADRB1 (0.58) | CYP2D6CYP3A4ADRB1DRD2 | |
| SCHEMBL188655 | 0.75 | GAA (0.40) | HRH3GAA | |
| SCHEMBL14983590 | 0.75 | ADRB1 (0.56) | KDM4EALDH1A1MAPTPKMHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516860-B | Benzoxazoles and oxazolopyridines being useful as FANUS kinases inhibitors | NOVARTIS AG | 2012-06-27 | — | — | CN | claimed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-3009428-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010067886-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| CN-101432284-A | Dihydropyrazolopyrimidinone derivative | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE2, WEE1, CDKL1 | KDM4E 1692/4885ALDH1A1 871/4885MAPT 4346/4885 |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | KDM4E 956/4885ALDH1A1 755/4885MAPT 4041/4885 |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | KDM4E 39/4885ALDH1A1 1554/4885MAPT 3116/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | KDM4E 956/4885ALDH1A1 755/4885MAPT 4041/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | KDM4E 956/4885ALDH1A1 755/4885MAPT 4041/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | KDM4E 956/4885ALDH1A1 755/4885MAPT 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.